Vision & Mission

Combining cancer vaccines
and T-cell therapies

ErVaccine Technologies develops breakthrough immunotherapies combining cancer vaccines and T-cell therapies based on the identification of new families of tumor antigens.

We are dedicated to discover more accurate tumor epitopes that are shared between patients. We focus on non-conventional epitopes derived from endogenous retroviruses (HERVs).

Our approach is based on new bioinformatics algorithms to identify potential epitopes that are validated by proteomics and immunology assays: from bioinformatics to proteomics.

About us

Latest News

  • Published On: February 23rd, 2023

    ErVaccine Technologies Announces Inaugural Members of Scientific Advisory Board

    Download the press release

    Lyon, France – February 23, 2023 – ErVaccine Technologies, a French biotech company developing next-generation therapeutic vaccines and cellular immunotherapies in oncology, announced today the inaugural […]

  • Published On: January 5th, 2023

    ErVaccine closes a €4.5 million financing round and prepares to start clinical trial with its first therapeutic cancer vaccine in 2023

    • ErVaccine is developing a therapeutic vaccine and cell therapy technology potentially applicable to many types of cancers
    • First vaccine […]
  • Published On: November 8th, 2022

    Neoantigen Based Therapies Summit 2022 – Boston

    Paola Bonaventura, project leader at ErVaccine Technologies,  has been giving a talk  entitled “Human Endogenous Retrovirus (HERVs) Represent a Source of Shared Tumour Epitopes Inducing High Avidity Cytotoxic T cells […]

Latest Publications & Abstracts

  • Categories: Publications & abstractsPublished On: March 1st, 2023

    A new review article in Science Advances 2023 – TCR-engineered T cell therapy in solid tumors: State of the art and perspectives

  • Categories: Publications & abstractsPublished On: June 28th, 2022

    Research article in American Journal of Hematology 2022 – HERVs characterize normal and leukemia stem cells and represent a source of shared epitopes for cancer immunotherapy

  • Categories: Publications & abstractsPublished On: June 16th, 2022

    Research Article in European Journal of Cancer journal 2022 – Tumor burden and antigen-specific T cell magnitude represent major parameters for clinical response to cancer vaccine and TCR-engineered T cell therapy

  • Categories: Publications & abstractsPublished On: January 27th, 2022

    Research Article in Science Advances 2022- Identification of shared tumor epitopes from endogenous retroviruses inducing high-avidity cytotoxic T cells for cancer immunotherapy